1 rich Libsyn https://www.libsyn.com 90 600 The VESALIUS-CV trial&amp;nbsp;demonstrated&amp;nbsp;that the PCSK9 inhibitor&amp;nbsp;evolocumab&amp;nbsp;significantly reduced the risk of a first major cardiovascular event in patients with diabetes who had no known significant atherosclerosis. These findings challenge current clinical practice, where PCSK9 inhibitors are typically reserved for secondary prevention in patients with prior heart&amp;nbsp;attack&amp;nbsp;or stroke. Importantly, the results support earlier, more proactive lipid-lowering intervention, showing benefit even before overt atherosclerotic disease is&amp;nbsp;evident. This&amp;nbsp;paradigm shift&amp;nbsp;underscores the opportunity to intensify preventive strategies and reduce cardiovascular risk earlier in high-risk populations.&amp;nbsp; &amp;nbsp; In this interview, Nanette Kass Wenger MD, MACC&amp;nbsp;and Nicholas Marston, MD&amp;nbsp;discuss&amp;nbsp;the&amp;nbsp;VESALIUS-CV&amp;nbsp;Trial.&amp;nbsp; &amp;nbsp; ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research http://accelaccorg.libsyn.com/website <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/42377120/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/204953055